Braveheart Bio Financial Statements
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
20.02+0.93 (+4.87%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Braveheart Bio has no annual income statement on file yet, so quarterly figures are shown instead.
Braveheart Bio revenue and earnings
Braveheart Bio reported a net loss of $15.0 million. Diluted earnings per share came in at -$2.51.
Summary generated from market data by MetaCap's automated system. Methodology
Braveheart Bio income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 15.88M | — | 381.00K | — |
| Research & Development | 11.13M | — | 0 | — |
| Operating Income | -15.88M | — | -381.00K | — |
| Other Income (Expense) | 894.00K | — | 0 | — |
| Net Income | -14.99M | -14.28M | -381.00K | -99.00K |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -2.51 | — | -0.14 | — |
| EPS (Diluted) | -2.51 | — | -0.14 | — |
| Shares Outstanding (Basic) | 7.40M | — | 2.79M | — |
| Shares Outstanding (Diluted) | 7.40M | — | 2.79M | — |
This table shows 4 quarterly periods of Braveheart Bio's income statement, from Q2 2026 back to Q? 2025, across 9 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow BRVE's reporting calendar. What is a income statement?